Insight Market na gaba (FMI), a cikin rahoton sa, yana aiwatar da ayyukan duniya baka sarrafa sakin fasahar samar da magunguna ta hanyar bada magani don yin rijistar haɓaka mai ban sha'awa a 7.2% CAGR a lokacin hasashen 2017 zuwa 2027. Kasuwar za ta zarce kudaden shiga da ya kai dalar Amurka miliyan 20,000 a shekarar 2017, kuma ana hasashen za ta kai kusan dalar Amurka miliyan 50,000 a ƙarshen 2027.
Masana'antar Magance Magungunan Magungunan Inganta a Arewacin Amurka Sun Amince don Samun Muhimmancin Bioavailability
Rahoton FMI ya kiyasta Arewacin Amurka zai kasance kasuwa mafi girma don fasahar isar da magunguna ta baki, tare da kiyasin tallace-tallace zai kai kusan dalar Amurka miliyan 20,000 nan da karshen 2027. Kasancewar hanyar da likitoci suka fi so ta hanyar sarrafa magunguna, buƙatar fasahar isar da magunguna ta baki ta kasance tana ganin karuwar masu amfani da ita a Arewacin Amurka. Bugu da kari, ci gaban baya-bayan nan a cikin isar da magunguna ya baiwa masana'antun sarrafa magunguna na baka a Arewacin Amurka damar cimma mahimmiyar rayuwa ta hanyar amfani da sabbin hanyoyin isar da magunguna. Ana kuma sa ran wannan zai haifar da buƙatar fasahar isar da magunguna ta baki a yankin.
Danna don samun Samfura: https://www.futuremarketinsights.com/reports/sample/rep-gb-4400
Koyaya, kara ayyukan bincike da suka danganci kwayoyin halitta, da kuma karfinsu wajen magance yanayin cutar kansar, hade da saka hannun jari na gwamnati a wadannan ayyukan binciken ana sa ran hakan zai kawo ci gaban kasuwa a Arewacin Amurka. Bugu da kari, kalubalen samarda tsari kamar kwatankwacin kasuwar da za a iya samu a kullun, da kuma ci gaban da aka samu wanda aka bayar da damar hana cin zarafi, ya haifar da fasahar bayar da magunguna ta baka wanda ake sa ran zai iya bunkasa ci gaban kasuwar a wannan yankin.
Sabuwar Abubuwan Harkokin Kemikal Sakamakon Ciwon Kayan Ganowa zuwa Kasuwancin Kasuwa a Yammacin Turai
Yammacin Turai za su yi rajista cikin sauri mafi sauri a cikin kasuwar fasahar isar da magunguna ta baka. Wannan haɓakar shine an danganta shi da kisan sabbin abubuwan kimiyyar sinadarai waɗanda ke haifar da babban binciken kayan aiki, waɗanda ke da ƙarancin ƙarfi da rayuwa. Wannan ya haifar da masana'antun masana'antu a wannan yankin don saka hannun jari ga hanyoyin bayar da magunguna tare da kyakkyawan sakamako na asibiti. Sakamakon kula da tsadar kayayyaki a cikin kasashen Yammacin Turai, fasahar inganta bioavailability zai kasance mafi tsarin tsarin bayar da magunguna. Ana tsammanin waɗannan abubuwan zasu iya haɓaka haɓakar kasuwar wannan yankin.
Koyaya, yawancin kamfanonin magunguna a Yammacin Turai suna da sarkar samar da hadaddun, wanda ko dai ba a amfani dashi ko kuma mara inganci. Rikicin sarkar samar da kayayyaki ana danganta shi da sassauƙan sassauƙa da tasiri mai tsada. Bugu da kari, takaita ingantacciyar rayuwa ta hanyar fasahar mallakar fasaha wani babban kalubale ne ga nau'ikan sakin magunguna na baka a wannan yankin. Abubuwa irin su an kiyasta zasu iya haɓaka haɓakar kasuwa a Yammacin Turai.
Tsarin Watsawa-Mai sarrafawa don Cigaba da Ci gaba-Bayan Tsarin fasahar Sakin magunguna a kasuwa
Ta hanyar fasahar sakin magunguna, tsarin sakin da ke sarrafa narke za a ci gaba da nema a kasuwa, sannan tsarin sakin mai sarrafa watsawa. Yawancin nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan allunan suna bin tsarin sakin da ke sarrafa narkewa. Abubuwan da ake samu daga tallace-tallace na tsarin sakin da ke sarrafa rushewa zai zarce dalar Amurka miliyan 10,000 a cikin 2017. Buƙatar tsarin isar da magunguna mai daidaita yanayin ruwa zai ci gaba da yin kasala a kasuwa.
Ana tsammanin sigogin sashi na ingantaccen sakin fasahar bayar da magunguna ta hanyar fasahar isar da magunguna ana ci gaba da zama a cikin kasuwa, yana fadadawa a cikin babban lambar CAGR ta 2027. Tallace-tallace na semisolid / ruwa / dakatarwa sashi nau'i zai yi rajistar kwatankwacin ƙananan CAGR fiye da na m siffofin sashi a cikin kasuwa ta 2027.
'Yan kasuwar kasuwar da aka gano a rahoton FMI sun hada da AstraZeneca Plc., Kamfanin Bristol-Myers Squibb, Sun Pharmaceuticals Industries Ltd, Abbott Laboratories, Merck & Co. Inc., Novartis AG, Pfizer Inc., Mylan NV, Sanofi, F. Hoffman-La -Roche Ltd., Johnson & Johnson Services, Inc., Vectura Group plc., GlaxoSmithKline plc.
Danna don samun zurfin TOC na wannan Rahoton: https://www.futuremarketinsights.com/reports/oral-controlled-release-drug-delivery-technology-market/table-of-content
Game da Sashen Kula da Lafiya a Halayen Kasuwa na gaba
Hasashen Kasuwa na gaba yana sauƙaƙe kamfanoni, gwamnati, masu saka hannun jari, da masu sauraro masu alaƙa a cikin sashin kiwon lafiya don ganowa da ba da fifikon mahimman abubuwan da suka dace da dabarun samfur, yanayin tsari, haɓakar fasaha, da sauran mahimman batutuwa don cimma nasara mai dorewa. Hanyarmu ta musamman don tattara bayanan sirri na kasuwa yana ba ku damar ƙirƙira sabbin hanyoyin dabarun kasuwanci don kasuwancin ku. Ƙara sani game da ɗaukar nauyin sassan mu anan
Game da Bayanin Kasuwanci na Gaba (FMI)
Hasashen Kasuwa na gaba (FMI) shine babban mai ba da bayanan sirri na kasuwa da sabis na tuntuɓar, yana yiwa abokan ciniki hidima a cikin ƙasashe sama da 150. FMI tana da hedikwata a Dubai, kuma tana da cibiyoyin bayarwa a Burtaniya, Amurka da Indiya. Sabbin rahotannin bincike na kasuwa na FMI da nazarin masana'antu suna taimaka wa 'yan kasuwa su gudanar da ƙalubale da yanke shawara mai mahimmanci tare da tabbaci da tsabta a tsakanin gasa ta karya wuya. Rahoton bincike na kasuwa na musamman da haɗin kai yana ba da fa'idodi masu dacewa waɗanda ke haifar da ci gaba mai dorewa. Tawagar ƙwararrun manazarta a FMI suna ci gaba da bin diddigin abubuwan da suka kunno kai da abubuwan da suka faru a cikin masana'antu da yawa don tabbatar da cewa abokan cinikinmu sun shirya don buƙatun masu amfani da su.
Saduwa da Mu:
Fadakarwar Kasuwa ta gaba
Naúrar No: AU-01-H Hasumiyar Zinare (AU), Ƙirar Ƙimar: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Don Tambayoyin Ciniki: [email kariya]
Don Tambayoyin Media: [email kariya]
Yanar Gizo: https://www.futuremarketinsights.com
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.
- Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027.
- However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America.
